124
Views
0
CrossRef citations to date
0
Altmetric
Polycystic ovary syndrome

The role of obstetrician-gynecologists and reproductive endocrinologists in the blood glucose management of polycystic ovary syndrome

, , , , , , , , , , , , & show all
Pages 1114-1120 | Received 18 May 2022, Accepted 11 Nov 2022, Published online: 29 Nov 2022

References

  • Harada M. Pathophysiology of polycystic ovary syndrome revisited: current understanding and perspectives regarding future research. Reprod Med Biol. 2022;21(1):e12487.
  • Bambhroliya Z, Sandrugu J, Lowe M, et al. Diabetes, polycystic ovarian syndrome, obstructive sleep apnea, and obesity: a systematic review and important emerging themes. Cureus. 2022;14(6):e26325.
  • Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631.
  • Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
  • Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231.
  • Barber TM, Dimitriadis GK, Andreou A, et al. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med. 2015;15(Suppl 6):s72–s76.
  • Goodman NF, Cobin RH, Futterweit W, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary Syndrome - Part 2. Endocr Pract. 2015;21(12):1415–1426.
  • Nöst X, Pferschy-Wenzig EM, Yu XT, et al. Comprehensive metabolic profiling of modified gegen qinlian decoction by ultra‑high‑performance liquid chromatography‑diode array detection‑Q‑exactive‑orbitrap‑electrospray ionization‑massspectrometry/mass spectrometry and application of high-performance thin-layer chromatography. World J Tradit Chin Med. 2021;7(1):11–32.
  • Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453–2455.
  • Pasquali R, Gambineri A. New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Invest. 2018;41(10):1123–1135.
  • Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–784.
  • DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–1460.
  • Chen LX, Hu DJ, Xu WF, et al. Identification and determination of fructooligosaccharides in snow chrysanthemum (Coreopsis tinctoria Nutt.). World J Tradit Chin Med. 2021;7(1):78–85.
  • Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–146.
  • Ollila MM, West S, Keinanen-Kiukaaniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus-a prospective population based cohort study. Hum Reprod. 2017;32(2):423–431.
  • Marchesan LB, Ramos RB, Spritzer PM. Metabolic features of women with polycystic ovary syndrome in Latin America: a systematic review. Front Endocrinol (Lausanne). 2021;12:759835.
  • Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339–352.
  • Marchesan LB, Spritzer PM. ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):579–587.e1.
  • Wild RA, Rizzo M, Clifton S, et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3):1073–1079.
  • Sir-Petermann T, Maliqueo M, Codner E, et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(12):4637–4642.
  • Harnois-Leblanc S, Hernandez MI, Codner E, et al. Profile of daughters and sisters of women with polycystic ovary syndrome: the role of proband’s glucose tolerance. J Clin Endocrinol Metab. 2022;107(3):e912–e923.
  • Chen X, Koivuaho E, Piltonen TT, et al. Association of maternal polycystic ovary syndrome or anovulatory infertility with obesity and diabetes in offspring: a population-based cohort study. Hum Reprod. 2021;36(8):2345–2357.
  • Gibson-Helm M, Dokras A, Karro H, et al. Knowledge and practices regarding polycystic ovary syndrome among physicians in Europe, North America, and internationally: an online questionnaire-based study. Semin Reprod Med. 2018;36(1):19–27.
  • Gu B, Zhu S, Ding X, et al. Effect of low-power visible-light-activated photodynamic therapy (PDT) on primary dysmenorrhea: a multicenter, randomized, double-blind, placebo-controlled trial. Int J Womens Health. 2022;14:1029–1036.
  • Dokras A, Saini S, Gibson-Helm M, et al. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107(6):1380–1386.e1.
  • Ma R, Zou Y, Wang W, et al. Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China. BMC Endocr Disord. 2021;21(1):182.
  • Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56(4):426–433.
  • Bilia AR, Bergonzi MC, Boulos JC, et al. Nanocarriers to enhance solubility, bioavailability, and efficacy of artemisinins. World J Tradit Chin Med. 2020;6(1):26–36.
  • Yang YP, Tasneem S, Daniyal M, et al. Lanostane tetracyclic triterpenoids as important sources for anti-inflammatory drug discovery. World J Tradit Chin Med. 2020;6(3):229–238.
  • Zhao X, Li Y, Chen M, et al. Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. Eur J Cancer Prev. 2015;24(1):27–36.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.